Patents by Inventor Robert E. Corringham

Robert E. Corringham has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of treating proliferative diseases
    Patent number: 9555040
    Abstract: Provided herein are methods of administering N-(5-tert-butyl-isoxazol-3-yl)-N?-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, or a pharmaceutically acceptable salt or solvate thereof, to human patients, including a specific patient population. Specifically, dosing, dosing schedules or dosing regimens are provided herein. Methods of treating proliferative diseases or FLT-3 mediated diseases in humans are also provided.
    Type: Grant
    Filed: September 17, 2014
    Date of Patent: January 31, 2017
    Assignee: Ambit Biosciences Corporation
    Inventors: Robert E. Corringham, Joyce K. James, Patrick B. O'Donnell
  • METHODS OF TREATING PROLIFERATIVE DISEASES
    Publication number: 20160051557
    Abstract: Provided herein are methods of administering N-(5-tert-butyl-isoxazol-3-yl)-N?-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, or a pharmaceutically acceptable salt or solvate thereof, to human patients, including a specific patient population. Specifically, dosing, dosing schedules or dosing regimens are provided herein. Methods of treating proliferative diseases or FLT-3 mediated diseases in humans are also provided.
    Type: Application
    Filed: September 17, 2014
    Publication date: February 25, 2016
    Inventors: Robert E. Corringham, Joyce K. James, Patrick B. O'Donnell
  • Methods of treating proliferative diseases
    Patent number: 8865710
    Abstract: Provided herein are methods of administering N-(5-tert-butyl-isoxazol-3-yl)-N?-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, or a pharmaceutically acceptable salt or solvate thereof, to human patients, including a specific patient population. Specifically, dosing, dosing schedules or dosing regimens are provided herein. Methods of treating proliferative diseases or FLT-3 mediated diseases in humans are also provided.
    Type: Grant
    Filed: May 14, 2010
    Date of Patent: October 21, 2014
    Assignee: Ambit Biosciences Corporation
    Inventors: Robert E. Corringham, Patrick B. O'Donnell, Joyce K. James
  • METHODS OF TREATING PROLIFERATIVE DISEASES
    Publication number: 20120258081
    Abstract: Provided herein are methods of administering N-(5-tert-butyl-isoxazol-3-yl)-N?-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, or a pharmaceutically acceptable salt or solvate thereof, to human patients, including a specific patient population. Specifically, dosing, dosing schedules or dosing regimens are provided herein. Methods of treating proliferative diseases or FLT-3 mediated diseases in humans are also provided.
    Type: Application
    Filed: May 14, 2010
    Publication date: October 11, 2012
    Applicant: AMBIT BIOSCIENCES CORPORATION
    Inventors: Robert E. Corringham, Patrick B. O'Donnell, Joyce K. James